login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SELECTA BIOSCIENCES INC (SELB) Stock News
USA
-
Nasdaq
- NASDAQ:SELB -
US8162121045
-
Common Stock
0.8812
USD
-0.08 (-8%)
Last: 11/13/2023, 8:15:05 PM
0.9
USD
+0.02 (+2.13%)
After Hours:
11/13/2023, 8:15:05 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SELB Latest News, Press Relases and Analysis
All
Press Releases
2 years ago - By: Cartesian Therapeutics, Inc.
- Mentions:
RNAC
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
2 years ago - By: Cartesian Therapeutics, Inc.
- Mentions:
RNAC
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
2 years ago - By: Brodsky & Smith LLC
- Mentions:
WAVD
GRPH
CSTR
ONB
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WaveDancer, Inc. (Nasdaq – WAVD), Selecta Biosciences, Inc. (Nasdaq – SELB), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
2 years ago - By: Benzinga
Analyst Ratings for Selecta Biosciences
3 years ago - By: Benzinga
Recap: Selecta Biosciences Q1 Earnings
2 years ago - By: Selecta Biosciences, Inc.
- Mentions:
RNAC
Selecta Biosciences Announces Merger with Cartesian Therapeutics
2 years ago - By: Selecta Biosciences, Inc.
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
2 years ago - By: Seeking Alpha
Selecta Biosciences files for $200M mixed shelf (NASDAQ:SELB)
3 years ago - By: Swedish Orphan Biovitrum AB
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB
2 years ago - By: Selecta Biosciences, Inc.
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
2 years ago - By: Seeking Alpha
- Mentions:
ABOS
ESTA
RCUS
BBIO
...
Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023 (BBIO)
2 years ago - By: Selecta Biosciences, Inc.
Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
3 years ago - By: Selecta Biosciences, Inc.
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
3 years ago - By: Selecta Biosciences, Inc.
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
3 years ago - By: InvestorPlace
- Mentions:
CISO
PEAR
CVKD
FRC
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
3 years ago - By: Seeking Alpha
Selecta stock surges ~20% as gout drug SEL-212 meets main goal in 2 trials
3 years ago - By: Selecta Biosciences, Inc.; Sobi
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
3 years ago - By: Selecta Biosciences, Inc.
Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3 years ago - By: InvestorPlace
- Mentions:
REGN
VRTX
HRMY
GNFT
...
The 7 Best Biotech Stocks to Buy for February 2023
3 years ago - By: Selecta Biosciences, Inc.
Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
3 years ago - By: Seeking Alpha
Selecta Biosciences stock rises 10% on license deal with Astellas for Xork
3 years ago - By: Selecta Biosciences, Inc.
Selecta Biosciences Provides Business Update and Outlook for 2023
3 years ago - By: Astellas Pharma Inc.
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
3 years ago - By: Selecta Biosciences, Inc.
Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program
3 years ago - By: Seeking Alpha
Selecta Biosciences appoints Protara Therapeutics's Blaine Davis as new CFO (NASDAQ:SELB)
Please enable JavaScript to continue using this application.